

Evidence2Health

Evangelos Oikonomou, MD, DPhil

Resident Physician, Internal Medicine

Physician Scientist Training Program

Yale School of Medicine

evangelos.oikonomou@yale.edu

Rohan Khera, MD, MS

Assistant Professor of Medicine

Yale School of Medicine

Attending Cardiologist, Yale New Haven Hospital

rohan.khera@yale.edu

Expertise: Data Science, Machine Learning, Advanced Statistical Modeling, Causal Inference



CarDS-Lab.org




Evidence2Health: Improving Health with Evidence




Current Inference

Evidence2Health


How Randomized Clinical trials are interpreted now: Average effects across groups



The Evidence2Health Approach: A patient-centered interpretation of trial effects



How does E2H achieve this?



Evidence2Health tool #1: ASSIST[®]


Anatomical OR Functional testing in patients with chest pain

Original **PROMISE** trial
(NEJM 2015)


No difference in
10,003 patients

E2H[™]
approach

E2H[™] phenomap of trial



Validation of E2H[™] recommendations in
an independent trial



An E2H[™] tool
for
personalized
trial
interpretation

Traditional approach

Average effect ~ null


“Patients can undergo either
anatomical or functional testing”

Traditional
trial
interpretation

ASSIST[©]



Web-based API
cards-lab.org/assist



HEALTH IT ANALYTICS
xtelligent HEALTHCARE MEDIA


InnovateHealthcare

Home News Features Interview

Population Health Precision Medicine Quality & Governance Tools & Strategies Analytics In Action

Machine Learning Helps Choose Best Test for Chest Pain

A machine learning tool can help providers choose between two non-invasive tests for patients with chest pain.



Become a Member

Z Drugs Medical Devices

may be negative in some

ABO

1 to patients with

Apr 29 2021

non dilemma in patients
, MS, and colleagues have

-MAIL

Evidence2Health tool #2: INSIGHT[©]



Canagliflozin
\$600 per month

↓ 15%

Cardiovascular risk
in Diabetes




16 Million Eligible
<1 Million Receiving



INSIGHT[©]

40% RISK REDUCTION
WITH THERAPY



NO BENEFIT WITH
THERAPY

Who can benefit from the E2H™ Approach to Clinical Trials



**Drug/Device
manufacturers**



**Health
systems/ACOs**




Health Insurers

E2H: Our Business Model

Evidence2Health™ Tools



Evidence2Health™ Optimization



E2H: Self-sustaining Business model

Evidence2Health™ Tools

Year 1-2

Computation – \$20K

Advertising - \$15K

Project Management – \$20K

Earnings:

\$10K to \$50K per deployment

Evidence2Health™ Optimization

Year 3-5

Computation – \$50K

Advertising - \$20K

Business Management – \$100K

Earnings:

\$50K to \$250K per 1 year contract

For more information contact

Rohan Khera, MD, MS

rohan.khera@yale.edu

OR

Evangelos Oikonomou, MD, DPhil

evangelos.oikonomou@yale.edu



CarDS-Lab.org